跳至主要内容
临床试验/NCT06805890
NCT06805890招募中不适用

Study of Tissue Repair in Inflammatory Bowel Disease Exploiting Organoid Technology

Assistance Publique Hopitaux De Marseille1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2025年7月24日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
60
试验地点
1
主要终点
Repair status of IBD patient's epithelial cells from inflamed mucosae

研究概览

简要总结

Inflammatory Bowel Diseases (IBD) are chronic inflammations of the gastrointestinal tract. Regardless of the etiology, a common trait of IBD pathogenesis is the inflammatory damage inflicted on the intestinal mucosa and the loss of intestinal epithelial barrier integrity. Therefore, understanding the mechanisms that govern IEC's capacity to maintain barrier function and to orchestrate mucosal healing is considered a major goal in translational research. The investigators are interested in understanding how the inflammatory environment present in the intestinal mucosa, of IBD patients influences epithelial cells capacity to govern repair. The complexities of the cytokine and metabolic milieu present in IBD patients render the study of the contribution of each cytokine, metabolite, and intracellular pathway extremely complicated. Therefore, most of the processes that govern tissue regeneration are studied with the use of mouse models that recapitulate one or multiple features of IBD and allow for genetical modifications of the gene and pathway of interest. While mouse models are uniquely suited to study the complex crosstalk between the immune system, the microbiota, and the intestinal epithelia, they introduce the important problem of species-specific differences, which can hamper the translational value of mouse studies.

To overcome these shortcomings, the investigators propose to explore the influence of cytokines and metabolites in digestive organoids derived from patients and controls. Importantly, it was demonstrated that gene expression and innate immune responses are altered in primary organoids derived from patients with IBD, including altered ability to proliferate, respond to cytokines, metabolic capacity, and efficiently form organoids suggesting that major differences between patient's and control's epithelial cell biology can be faithfully replicated in this system.

Given these premises, the investigators propose the following objectives:

Primary objective:

The main objective of this study is to establish that patient's epithelial cells from inflamed mucosae have decreased ability to repair the intestinal mucosa, as compared to epithelial cells from non-inflamed regions in the same patient, or to control subject with no inflammatory digestive diseases.

The investigators will explore this question both deriving organoids from clinical samples and exposing them to pro inflammatory cytokines and metabolites in vitro, as well as by analyzing repair responses from the aforementioned clinical samples ex vivo.

Secondary objective

The secondary goals of this study are:

- To compare organoids derived from: epithelia in inflamed mucosa of IBD patients, epithelia in non-inflamed mucosa of IBD patients, and epithelia from the mucosa of non-IBD controls in their capacity to mount a repair response in response to inflammatory cytokines or luminal metabolites.

Namely the investigators will evaluate the following parameters:

  • Their capacity to proliferate.
  • Their ability to survive treatment with pro-inflammatory cytokines
  • The activation of intracellular pathways associated with cell death.
  • Their overall metabolic activity.
  • The balance between stem and differentiated epithelial cell types.
  • The transcriptional activation of protective pathways such as those associated with proliferation, migration, differentiation and cell survival.
  • To evaluate hallmarks of tissue repair in biopsies derived from epithelia in inflamed mucosa of IBD patients, epithelia in non-inflamed mucosa of IBD patients, and epithelia from the mucosa of non-IBD controls, and to correlate them to the levels of inflammatory cytokines, luminal metabolites and overall disease severity. Namely the investigators will evaluate the following parameters:
  • The abundance of proliferating cells.
  • The activation of intracellular pathways associated with cell death and survival.
  • Their overall metabolic activity.
  • The balance between stem and differentiated epithelial cell types.
  • The transcriptional activation of protective pathways such as those associated with proliferation, migration, differentiation and cell survival.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Patients of either sex aged 18 years or older
  • •Patient that have read the information form and signed consent
  • •Patient covered with health insurance
  • •Patients with Crohn's Disease or ulcerative colitis in accordance with accepted clinical, endoscopic, histological and/or radiologic criteria, regardless of the level, severity of the disease or duration of disease progression.
  • •Patients with colonic involvement of Crohn's disease or ulcerative colitis
  • •Patients undergoing a screening colonoscopy in the context of IBD disease follow-up OR undergoing intestinal resection for IBD disease aggravation
  • •For control group the inclusion criteria will be:
  • •Patients of either sex aged 18 years or older
  • •Patient that have read the information form and signed consent
  • •Patient covered with health insurance
  • •Patients undergoing a screening colonoscopy in the context of a family history of colonic neoplasia, follow-up of colonic polyps or functional intestinal disorders OR undergoing intestinal resection for intestinal neoplasia, occlusive syndrome or colostomy
  • •The non-inclusion criteria for IBD group will be:
  • •Contraindication to the anaesthetic or colonoscopy procedure
  • •Patients without colonic involvement of Crohn's disease or ulcerative colitis
  • •Patients of Adults without legal capacity
  • •Patients in Health and Social Establishments
  • •Persons in emergency situations
  • •Persons deprived of their liberty
  • •Non-affiliated to a social security scheme
  • •Absence or refusal of the informed consent
  • •The non-inclusion criteria for control group will be:
  • •IBD disease revealed during colonoscopy or gastrointestinal resection
  • •Patient suffering from Immune-Mediated Inflammatory Diseases (IMIDs)
  • •Contraindication to the anaesthetic or colonoscopy procedure
  • •Patients of Adults without legal capacity
  • •Patients in Health and Social Establishments
  • •Persons in emergency situations
  • •Persons deprived of their liberty
  • •Non-affiliated to a social security scheme
  • •Absence or refusal of the informed consent

排除标准

  • 未提供

研究组 & 干预措施

Control group

Sham Comparator

Patients of either sex aged 18 years or older and undergoing a screening colonoscopy in the context of a family history of colonic neoplasia, follow-up of colonic polyps or functional intestinal disorders OR undergoing intestinal resection for intestinal neoplasia, occlusive syndrome or colostomy

干预措施: Colonoscopy - biopsies in healthy tissue (Procedure)

Control group

Sham Comparator

Patients of either sex aged 18 years or older and undergoing a screening colonoscopy in the context of a family history of colonic neoplasia, follow-up of colonic polyps or functional intestinal disorders OR undergoing intestinal resection for intestinal neoplasia, occlusive syndrome or colostomy

干预措施: Surgical resection - healthy mucous membrane (Procedure)

IBD group

Experimental

Patients of either sex aged 18 years or older with Crohn's Disease or ulcerative colitis in accordance with accepted clinical, endoscopic, histological and/or radiologic criteria, regardless of the level, severity of the disease or duration of disease progression or patients undergoing a screening colonoscopy in the context of IBD disease follow-up OR undergoing intestinal resection for IBD disease aggravation

干预措施: Colonoscopy - IBD inflamed tissue (Procedure)

IBD group

Experimental

Patients of either sex aged 18 years or older with Crohn's Disease or ulcerative colitis in accordance with accepted clinical, endoscopic, histological and/or radiologic criteria, regardless of the level, severity of the disease or duration of disease progression or patients undergoing a screening colonoscopy in the context of IBD disease follow-up OR undergoing intestinal resection for IBD disease aggravation

干预措施: Surgical resection - IBD inflamed mucous membrane (Procedure)

IBD group

Experimental

Patients of either sex aged 18 years or older with Crohn's Disease or ulcerative colitis in accordance with accepted clinical, endoscopic, histological and/or radiologic criteria, regardless of the level, severity of the disease or duration of disease progression or patients undergoing a screening colonoscopy in the context of IBD disease follow-up OR undergoing intestinal resection for IBD disease aggravation

干预措施: Surgical resection - healthy mucous membrane (Procedure)

结局指标

主要结局

Repair status of IBD patient's epithelial cells from inflamed mucosae

时间窗: From enrollmet to the end of following at 1 month

To establish that patient's epithelial cells from inflamed mucosae have decreased ability to repair the intestinal mucosa, as compared to epithelial cells from non-inflamed regions in the same patient, or to control subject with no inflammatory digestive diseases

次要结局

  • 3. Explore the activation of molecular mechanisms identified in patient biopsies and correlate them with the inflammatory environment present in the patient's tissues(From enrollment to the end of following at 1 month)
  • Evaluate the molecular mechanism involved in the reduced capacity of epithelial cells of IBD patients to repair intestinal mucosa(From enrollment to the end of following at 1 month)
  • Genetically determine the involvement of cell death and protective pathways that reduce repair capacity in patients.(From enrollment to the end of following at 1 month)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验